• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA releases industry guidance on antibiotics

December 1, 2003
Daniel R. Verdon

Cleveland-The Food and Drug Administration (FDA) released its long-anticipated risk-assessment guidance for food animals to help safeguard against the emergence of antibiotic resistance in people.

Cleveland-The Food and Drug Administration (FDA) released its long-anticipated risk-assessment guidance for food animals to help safeguard against the emergence of antibiotic resistance in people.

Dr. Linda Tollefson, deputy director for FDA's Center for Veterinary Medicine (CVM), explains, "What this document represents is a risk-based approach to help prevent antimicrobial resistance that may result from the use of antimicrobial drugs in food producing animals."

This new approach will apply to therapeutic and non-therapeutic antimicrobial drugs intended for food-producing animals. FDA adds that it will lead to a review of all existing approvals.

Tollefson explains that CVM has taken on many initiatives addressing the issue of antimicrobial resistance. There are many sources of the problem, including the inappropriate use of antibiotics in people. However, this document simply represents agriculture's role in preventing the problem, she adds.

Dr. Linda Tollefson

Industry is not disagreeing either.

According to the Animal Health Institute (AHI), a national organization representing animal health manufacturers, it's a better approach to regulating antibiotics.

Advertisement

"The new guidance is a superior approach to regulating antibiotics, compared to the European phase-out of antibiotics for growth promotion or to legislation proposed in the U.S. Congress. The new guidance bases decisions on science and risk assessment, rather than politics, and requires drugs to be looked at individually rather than lumping them all together, AHI says.

Alexander Mathews, AHI president and CEO, says, "This risk-based approach will allow FDA to make sound management decisions that protect public health from the potential transfer of antibiotic resistance bacteria from animals to humans. At the same time, it will preserve the important benefits of using antibiotics to protect animal health, he adds.

Alexander S. Mathews

This new risk-assessment guidance will apply to all antibiotics approved for use in food-producing animals. FDA explains, the guidance provides a scientific process for assessing the likelihood that an antimicrobial drug used to treat an animal may cause an antimicrobial resistance problem in humans consuming meat or other byproducts from that animal.

"This process can help prevent antimicrobial drugs with a high risk of causing such problems from being improperly used in food-producing animals, and thereby potentially leading to antimicrobial resistance in humans," FDA says.

The new guidance encourages drug sponsors to use a risk assessment process to demonstrate that an antimicrobial drug used to treat food-producing animals will not create a risk of antimicrobial resistant bacteria likely to lead to human health problems.

Stephen Sundlof, DVM, MPH, director of CVM, adds, "This guidance uses science to develop a risk-based approach to the issue of antimicrobial resistance. It permits us to help protect human health while giving veterinarians and livestock producers the tools they need to treat animals."

Dr. Stephen Sundlof

Details, details

The agency has devised a three-part system for determining an antimicrobial drug's potential risk to humans if used to treat food-producing animals. The three parts include:

  • A "release assessment," which determines the probability that resistant bacteria will be present in an animal as a result of the use of the new antimicrobial drug.

  • An "exposure estimate" to gauge the likelihood that humans might ingest resistant bacteria.

  • A "consequence assessment," which takes into account the chances human exposure to the resistant bacteria would result in adverse human health consequences.

Once the risk estimation has been completed, it leads to a ranking of drugs: high, medium, low. These risk-based rankings are associated with certain risk management categories.

  • Category 1 (high risk estimate): strictly limited use conditions.

  • Category 2 (medium risk estimate): intermediate restriction on drug use.

  • Category 3 (low risk estimate): least restriction on drug use.

CVM says it also has risk management strategies for drugs that rank high. For example, an application for approval could be flat-out denied, or approved under specific-use conditions. FDA could place limits on marketing, including prescriptions or Veterinary Feed Directive, prohibition on extra-label use or even limits on duration/method of administration.

Included in the new document is a revised ranking system for antimicrobial drugs and their importance to human medicine.

Table 1

Examples include:

  • Critically important to human medicine: Third-generation cephalosporins, macrolides, fluoroquinolones.

  • Highly important to human medicine: Fourth-generation cephalosporins, aminoglycosides, clindamycin.

  • Important to human medicine: First- and second-generation cephalosporins, monobactams, quinolones.

Tollefson adds that FDA consciously decided to release this risk assessment as a guidance document rather than regulation because it is much easier to amend due to changing science.

Related Content:

RegulatoryFood Animals
Feed control officials reassert copper concentration guidelines
Feed control officials reassert copper concentration guidelines
What's going on with xylazine becoming a street drug?
What's going on with xylazine becoming a street drug?
USDA aims to strengthen handling regulations for exotic animals in exhibition
USDA aims to strengthen handling regulations for exotic animals in exhibition

Advertisement

Latest News

American Veterinary Medical Foundation welcomes new executive director

Details of new pet performance supplement line revealed

Veterinary scene Down Under: DEI advancements, plus title protection and more

Temple Grandin receives honorary degree from Kansas State University College of Veterinary Medicine

View More Latest News
Advertisement